The Evidence-based CKD Clinic: Changing Practice with SGLT2 Inhibition

Published: 20 January 2022

  • Views:

    Views Icon 65612
  • Likes:

    Heart Icon 7
  • episode_image
    11m 41s
    Part 3 The Follow-up
    David Wheeler, Carol Pollock, Sunita Bavanandan
Average (ratings)
No ratings
Your rating


Starting at the waiting room, then through to the consultation, follow-up and patient discharge, explore the role of SGLT2 inhibition in treating CKD, based on efficacy data.


Chair, Prof David Wheeler (University College London, UK) leads the patient-based, data-supported discussion on the renal efficacy and implementation of SGLT2 inhibitors in the treatment of CKD alongside Prof Carol Pollock and Dr Sunita Bavanandan.

This symposium was endorsed by UCL and supported by an unrestricted grant from AstraZeneca

After this educational symposium, delegates will:

  • Recognise SGLT2 inhibitors as part of the evidence-based CKD treatment landscape
  • Understand data supporting the renal efficacy of SGLT2 inhibition in relation to the treatment and clinical outcomes of CKD
  • Be able to identify the optimal time to initiate SGLT2 inhibitors in the treatment ofCKD

Target Audience

  • Cardiologists
  • Nephrologists

More from this programme

Part 1

The Waiting Room

Overview of the symposium agenda followed by an introduction of a patient with T2D and CKD stage 3/4 who has recently been referred for a nephrologist consultation (patient is taking antihypertensive therapies, including sub-optimal RAASi therapy).

Part 2

The Consultation

A structured discussion around the most appropriate therapeutic regimen for the patient case, with supportive clinical evidence presented throughout. This session explores the following; Data to support the effective use of SGLT2 inhibitor therapy in DKD across eGFR strata; Data to support the effective use of SGLT2 inhibitor therapy in the following hypothetical scenarios: Patient presents with NDKD, IgA nephropathy, or FSGS; Safety considerations for the use of SGLT2 inhibitors in patients with CKD and Practical considerations with regards to sequencing and dosing / titration.

Part 3

The Follow-up

Data-supported discussion around the most appropriate course of action to take following eGFR decline at a patient follow-up visit. This session will address the following; Comparability of eGFR trajectories with SGLT2 and RAAS inhibitor therapies, The complementary mechanisms of SGLT2 and RAAS inhibitor therapies, Considerations for recommended eGFR cut-offs with SGLT2 inhibitor therapy.

Part 4

Patient Discharged

Closing remarks and summary of key take-home considerations for the evidence-based treatment of patients with CKD.

Part 5

Q&A and Panel Discussion

A discussion and Q&A with our panel.

Faculty Biographies

David Wheeler

David Wheeler

Professor of Kidney Medicine

David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.

Prof Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, intravenous iron, sodium–glucose co-transporter 2 inhibitors and hypoxia-inducible factor stabilisers in patients with CKD.

Prof Wheeler has also been involved in the development of clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-Chair between 2012 and 2019. His ongoing roles include serving as the National Specialty Lead for the…

View full profile